Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by LtGhoston Mar 19, 2020 10:00am

55 Views

Post# 30825808

RE:RE:If you vote yes to this planned takeover stero/bassada and

But why we have to acquire Stero NOW? At this stage, acquisition of Stero will only do harm to Kly shareholder. We don't need Stero now. If everything go through, after the 10 million pp, I don't think current kly shareholders will have 25% of the "new" kly.

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!